Identification

Name
Tolfenamic Acid
Accession Number
DB09216
Type
Small Molecule
Groups
Approved, Investigational
Description

Tolfenamic acid, with the formula N-(2-methyl-3-chlorphenyl)-anthranilic acid, is a nonsteroidal anti-inflammatory agent.[2] It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment for migraine under the name of Clotam.[10] In the US, it presents a Status class I by the FDA. By the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.[9]

Structure
Thumb
Synonyms
Not Available
International/Other Brands
Clotam (GEA Farmaceutisk Fabrik)
Categories
UNII
3G943U18KM
CAS number
13710-19-5
Weight
Average: 261.704
Monoisotopic: 261.05565634
Chemical Formula
C14H12ClNO2
InChI Key
YEZNLOUZAIOMLT-UHFFFAOYSA-N
InChI
InChI=1S/C14H12ClNO2/c1-9-11(15)6-4-8-12(9)16-13-7-3-2-5-10(13)14(17)18/h2-8,16H,1H3,(H,17,18)
IUPAC Name
2-[(3-chloro-2-methylphenyl)amino]benzoic acid
SMILES
CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O

Pharmacology

Indication

In the information for tolfenamic acid, it is stated that this drug, being an NSAID, is effective in treating the pain associated with the acute attack of migraines in adults.[11]

Pharmacodynamics

Studies have shown that tolfenamic acid presents a non-dose dependent partial inhibition of irritant-induced temperature rise as well as a dose-dependent inhibition of skin edema. By studying its NSAID properties more closely, it was noted a dose-related inhibition of serum thromboxane which indicated the inhibition of COX-1. In the same line, there was noted a inhibition of prostaglandin E2 synthesis which marks a related COX-2 inhibition.[3] The maximal inhibition of thromboxane was greater than 80% as well as is proven to be a potent prostaglandin E inhibitor.[4]

Mechanism of action

Tolfenamic acid inhibits the biosynthesis of prostaglandins, and it also presents inhibitory actions on the prostaglandin receptors.[2] As commonly thought, the mechanism of action of tolfenamic acid is based on the major mechanism of NSAIDs which consists of the inhibition of COX-1 and COX-2 pathways to inhibit prostaglandin secretion and action and thus, to exert its anti-inflammatory and pain-blocking action. Nonetheless, some report currently indicates that tolfenamic acid inhibits leukotriene B4 chemotaxis of human polymorphonuclear leukocytes leading to an inhibition of even 25% of the chemotactic response. This activity is a not ligand specific additional anti-inflammatory mechanism of tolfenamic acid.[5]

TargetActionsOrganism
AProstaglandin G/H synthase 1
antagonist
Human
AProstaglandin G/H synthase 2
antagonist
Human
Absorption

Tolfenamic acid pharmacokinetic is marked by a short tmax of 0.94-2.04 h.[3] It also presented a linear pharmacokinetic profile with an AUC from 13-50 mcg/ml.h if administered in a dose of 2-8 mg/kg respectively.[4] The oral absorption is delayed and it gives a mean lag-time to absorption of 32 min. The peak plasma concentration of 11.1 mcg/ml.[6] The bioavailability of tolfenamic acid is around 75%.[8]

Volume of distribution

The volume of distribution is of 1.79-3.2 L/kg.[3] When tested intravenously, the reported steady-state volume of distribution was 0.33 L/kg.[6]

Protein binding

Tolfenamic acid presents high protein binding properties reaching 99.7% of the administered dose.[1] Studies have studied the changes in protein binding depending on the presence of certain disorders that modify the dialysis equilibrium. These studies verify that modifications in blood creatinine, urea and bilirubin can significantly alter the concentration of unbound tolfenamic acid. The main binding structure is predicted to be related to lipid membrane structures.[7]

Metabolism

The first pass metabolism accounts for 20% of the administered dose of tolfenamic acid.[8] Urine metabolite studies have demonstrated the identification of five metabolites from which three of them are monohydroxylated, one is monohydroxylated and hydroxylated and one last metabolite that presented and oxidized methyl group to form a carboxyl group.[8] Two of these hydroxylated metabolites are N-(2-hydroxymethyl-3-chlorophenyl)-anthranilic acid and N-(2-hydroxymethyl-3-chloro-4-hydroxyphenyl)-anthranilic acid.[12]

Route of elimination

Tolfenamic acid is cleared relatively fast and it undergoes by hepatic metabolism where the produced metabolites are renally cleared as glucuronic acid conjugates.[8] Most of the elimination occurs by extrarenal mechanisms in which the unchanged drug together with its glucuronide in urine accounts for only 8.8% of the administered dose.[1]

Half life

The estimated half-life of tolfenamic acid is 8.01-13.50 hours.[3] When tested intravenously, the reported half-life was 6.1h.[6]

Clearance

The estimated clearance rate of tolfenamic acid is 0.142-0.175 L.h/kg.[3] When tested intravenously, the reported clearance rate was 72.4 ml.h/kg.[6]

Toxicity

Tolfenamic acid has a relatively low acute toxicity with LD50 values in 200-1000 mg/kg. The metabolites of tolfenamic acid are reported to have an even less important toxicity. Some of the expected toxicity is related to the presence of gastrointestinal effects such as gut ulceration and renal papillitis.[12]

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with (R)-warfarin.Experimental
(S)-WarfarinThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with (S)-Warfarin.Experimental, Investigational
4-hydroxycoumarinThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with 4-hydroxycoumarin.Experimental
AbafunginThe therapeutic efficacy of Abafungin can be increased when used in combination with Tolfenamic Acid.Investigational
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Abciximab.Approved
AcebutololTolfenamic Acid may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Tolfenamic Acid.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Acenocoumarol.Approved, Investigational
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Tolfenamic Acid.Approved, Vet Approved
AcetohexamideThe protein binding of Acetohexamide can be decreased when combined with Tolfenamic Acid.Approved, Investigational, Withdrawn
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tolfenamic Acid.Approved, Vet Approved
AlbaconazoleThe therapeutic efficacy of Albaconazole can be increased when used in combination with Tolfenamic Acid.Investigational
AlclofenacThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of gastrointestinal irritation can be increased when Alclometasone is combined with Tolfenamic Acid.Approved
AlcuroniumTolfenamic Acid may increase the neuromuscular blocking activities of Alcuronium.Experimental
AldosteroneThe risk or severity of gastrointestinal irritation can be increased when Aldosterone is combined with Tolfenamic Acid.Experimental, Investigational
Alendronic acidThe risk or severity of gastrointestinal bleeding can be increased when Tolfenamic Acid is combined with Alendronic acid.Approved
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Tolfenamic Acid.Approved, Investigational
AliskirenThe risk or severity of renal failure and hypertension can be increased when Tolfenamic Acid is combined with Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Alminoprofen.Experimental
AlprenololTolfenamic Acid may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
AlteplaseThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Alteplase.Approved
AmbrisentanThe therapeutic efficacy of Ambrisentan can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
AmcinonideThe risk or severity of gastrointestinal irritation can be increased when Amcinonide is combined with Tolfenamic Acid.Approved
AmediplaseThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Amediplase.Investigational
AmikacinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Amiloride.Approved
AminophenazoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Aminophenazone.Approved, Withdrawn
AmiodaroneThe metabolism of Tolfenamic Acid can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Tolfenamic Acid.Approved
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Tolfenamic Acid.Approved
AmobarbitalThe metabolism of Tolfenamic Acid can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Tolfenamic Acid.Approved
Amphotericin BTolfenamic Acid may decrease the nephrotoxic activities of Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Tolfenamic Acid can be decreased when combined with Amprenavir.Approved, Investigational
AnagrelideThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Anagrelide.Approved
AncrodThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Ancrod.Approved, Investigational
AnisodamineTolfenamic Acid may decrease the antihypertensive activities of Anisodamine.Investigational
AnistreplaseThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Anistreplase.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tolfenamic Acid.Approved, Investigational
Antithrombin III humanThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Antrafenine.Approved
ApalutamideThe serum concentration of Tolfenamic Acid can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Apixaban.Approved
ApramycinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Apramycin.Experimental, Vet Approved
AprepitantThe serum concentration of Tolfenamic Acid can be increased when it is combined with Aprepitant.Approved, Investigational
ArbekacinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Arbekacin.Approved, Investigational
ArdeparinThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Argatroban.Approved, Investigational
AripiprazoleThe risk or severity of hypotension can be increased when Aripiprazole is combined with Tolfenamic Acid.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Tolfenamic Acid.Approved, Investigational
ArotinololThe risk or severity of hypotension can be increased when Arotinolol is combined with Tolfenamic Acid.Investigational
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Tolfenamic Acid.Approved
AstaxanthinThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Astaxanthin.Investigational
AtazanavirThe metabolism of Tolfenamic Acid can be decreased when combined with Atazanavir.Approved, Investigational
AtenololTolfenamic Acid may decrease the antihypertensive activities of Atenolol.Approved
AtracuriumTolfenamic Acid may increase the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateTolfenamic Acid may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tolfenamic Acid.Withdrawn
Azilsartan medoxomilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azilsartan medoxomil is combined with Tolfenamic Acid.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Tolfenamic Acid.Investigational
BacitracinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Bacitracin.Approved, Vet Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Tolfenamic Acid.Approved, Investigational
BarbexacloneThe metabolism of Tolfenamic Acid can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Tolfenamic Acid can be increased when combined with Barbital.Illicit
Beclomethasone dipropionateThe risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Tolfenamic Acid.Approved, Investigational
BefunololTolfenamic Acid may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Bekanamycin.Experimental
BemiparinThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Bemiparin.Approved, Investigational
BenazeprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Benazepril.Approved, Investigational
BenazeprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Benazeprilat.Experimental
BendazacThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tolfenamic Acid.Approved
BenorilateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Tolfenamic Acid.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Tolfenamic Acid.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Benzydamine.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Tolfenamic Acid.Approved, Withdrawn
BeraprostThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Beraprost.Investigational
BesifloxacinTolfenamic Acid may increase the neuroexcitatory activities of Besifloxacin.Approved
BetamethasoneThe risk or severity of gastrointestinal irritation can be increased when Betamethasone is combined with Tolfenamic Acid.Approved, Vet Approved
BetaxololTolfenamic Acid may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BethanidineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Tolfenamic Acid.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Tolfenamic Acid.Approved, Investigational
BevantololTolfenamic Acid may decrease the antihypertensive activities of Bevantolol.Approved
BietaserpineThe therapeutic efficacy of Bietaserpine can be decreased when used in combination with Tolfenamic Acid.Experimental
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Tolfenamic Acid.Approved
BisoprololTolfenamic Acid may decrease the antihypertensive activities of Bisoprolol.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Tolfenamic Acid.Approved
BivalirudinThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Tolfenamic Acid can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololTolfenamic Acid may decrease the antihypertensive activities of Bopindolol.Approved
BosentanThe serum concentration of Tolfenamic Acid can be decreased when it is combined with Bosentan.Approved, Investigational
BQ-123The therapeutic efficacy of BQ-123 can be decreased when used in combination with Tolfenamic Acid.Investigational
BretyliumThe therapeutic efficacy of Bretylium can be decreased when used in combination with Tolfenamic Acid.Approved
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Tolfenamic Acid.Approved, Investigational
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Tolfenamic Acid.Approved
BrinaseThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Brinase.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tolfenamic Acid.Approved
BromocriptineThe risk or severity of hypotension can be increased when Bromocriptine is combined with Tolfenamic Acid.Approved, Investigational
BucindololTolfenamic Acid may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Tolfenamic Acid.Approved
BufexamacThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Bufexamac.Approved, Experimental
BufuralolTolfenamic Acid may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Tolfenamic Acid.Approved
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Tolfenamic Acid.Investigational
BupranololTolfenamic Acid may decrease the antihypertensive activities of Bupranolol.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Tolfenamic Acid.Approved
CadralazineThe therapeutic efficacy of Cadralazine can be decreased when used in combination with Tolfenamic Acid.Experimental
Calcium AcetateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium Phosphate.Approved
CandesartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Candesartan is combined with Tolfenamic Acid.Experimental
Candesartan cilexetilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Candesartan cilexetil is combined with Tolfenamic Acid.Approved
CandoxatrilThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Tolfenamic Acid.Experimental
CangrelorThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Cangrelor.Approved
CapreomycinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Capreomycin.Approved
CaptoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Captopril.Approved
CarbamazepineThe metabolism of Tolfenamic Acid can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Carbaspirin calcium.Experimental, Investigational
CarboplatinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Carboplatin.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Tolfenamic Acid.Approved
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
CarbutamideThe protein binding of Carbutamide can be decreased when combined with Tolfenamic Acid.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Tolfenamic Acid.Approved, Vet Approved, Withdrawn
CarteololTolfenamic Acid may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolTolfenamic Acid may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational, Nutraceutical, Vet Approved
CefacetrileThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Cefacetrile.Approved
CefaclorThe risk or severity of nephrotoxicity can be increased when Cefaclor is combined with Tolfenamic Acid.Approved
CefadroxilThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Cefadroxil.Approved, Vet Approved, Withdrawn
CefalotinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Cefalotin.Approved, Investigational, Vet Approved
CefamandoleThe risk or severity of nephrotoxicity can be increased when Cefamandole is combined with Tolfenamic Acid.Approved, Investigational
CefapirinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Cefapirin.Approved, Vet Approved
CefatrizineThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Cefatrizine.Experimental
CefazedoneThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Cefazedone.Experimental
CefazolinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Cefazolin.Approved
CefbuperazoneThe risk or severity of nephrotoxicity can be increased when Cefbuperazone is combined with Tolfenamic Acid.Experimental
CefcapeneThe risk or severity of nephrotoxicity can be increased when Cefcapene is combined with Tolfenamic Acid.Experimental
CefditorenThe risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Tolfenamic Acid.Approved, Investigational
CefepimeThe risk or severity of nephrotoxicity can be increased when Cefepime is combined with Tolfenamic Acid.Approved, Investigational
CefetametThe risk or severity of nephrotoxicity can be increased when Cefetamet is combined with Tolfenamic Acid.Experimental
CefmenoximeThe risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Tolfenamic Acid.Approved
CefmetazoleThe risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Tolfenamic Acid.Approved, Investigational
CefminoxThe risk or severity of nephrotoxicity can be increased when Cefminox is combined with Tolfenamic Acid.Approved
CefodizimeThe risk or severity of nephrotoxicity can be increased when Cefodizime is combined with Tolfenamic Acid.Experimental
CefonicidThe risk or severity of nephrotoxicity can be increased when Cefonicid is combined with Tolfenamic Acid.Approved, Investigational
CefoperazoneThe risk or severity of nephrotoxicity can be increased when Cefoperazone is combined with Tolfenamic Acid.Approved, Investigational
CeforanideThe risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Tolfenamic Acid.Approved
CefotaximeThe risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Tolfenamic Acid.Approved
CefotetanThe risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Tolfenamic Acid.Approved
CefotiamThe risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Tolfenamic Acid.Approved, Investigational
CefoxitinThe risk or severity of nephrotoxicity can be increased when Cefoxitin is combined with Tolfenamic Acid.Approved
CefozopranThe risk or severity of nephrotoxicity can be increased when Cefozopran is combined with Tolfenamic Acid.Experimental
CefpiramideThe risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Tolfenamic Acid.Approved
CefpiromeThe risk or severity of nephrotoxicity can be increased when Cefpirome is combined with Tolfenamic Acid.Approved
CefpodoximeThe risk or severity of nephrotoxicity can be increased when Cefpodoxime is combined with Tolfenamic Acid.Approved, Vet Approved
CefprozilThe risk or severity of nephrotoxicity can be increased when Cefprozil is combined with Tolfenamic Acid.Approved
CefradineThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Cefradine.Approved
CefroxadineThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Cefroxadine.Withdrawn
CefsulodinThe risk or severity of nephrotoxicity can be increased when Cefsulodin is combined with Tolfenamic Acid.Experimental
Ceftaroline fosamilThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Ceftaroline fosamil.Approved, Investigational
CeftazidimeThe risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Tolfenamic Acid.Approved
CeftezoleThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Ceftezole.Experimental
CeftibutenThe risk or severity of nephrotoxicity can be increased when Ceftibuten is combined with Tolfenamic Acid.Approved, Investigational
CeftizoximeThe risk or severity of nephrotoxicity can be increased when Ceftizoxime is combined with Tolfenamic Acid.Approved, Investigational
CeftobiproleThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Ceftobiprole.Approved, Investigational
CeftriaxoneThe risk or severity of nephrotoxicity can be increased when Ceftriaxone is combined with Tolfenamic Acid.Approved
CefuroximeThe risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Tolfenamic Acid.Approved
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Tolfenamic Acid.Approved, Investigational
CeliprololTolfenamic Acid may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CephalexinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Cephalexin.Approved, Investigational, Vet Approved
CephaloglycinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Cephaloglycin.Approved
CephaloridineThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Cephaloridine.Approved, Withdrawn
Cephalothin GroupThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Cephalothin Group.Experimental
CeritinibThe serum concentration of Tolfenamic Acid can be increased when it is combined with Ceritinib.Approved
CertoparinThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Certoparin.Approved, Investigational
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tolfenamic Acid.Approved, Vet Approved
ChlorpromazineThe risk or severity of hypotension can be increased when Chlorpromazine is combined with Tolfenamic Acid.Approved, Investigational, Vet Approved
ChlorpropamideThe protein binding of Chlorpropamide can be decreased when combined with Tolfenamic Acid.Approved, Investigational
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tolfenamic Acid.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Tolfenamic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Tolfenamic Acid.Approved
CiclesonideThe risk or severity of gastrointestinal irritation can be increased when Ciclesonide is combined with Tolfenamic Acid.Approved, Investigational
CicletanineThe therapeutic efficacy of Cicletanine can be decreased when used in combination with Tolfenamic Acid.Investigational
CilazaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Cilazapril.Approved
CimetidineThe serum concentration of Tolfenamic Acid can be increased when it is combined with Cimetidine.Approved, Investigational
CimicoxibThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Cimicoxib.Investigational
CinoxacinTolfenamic Acid may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinTolfenamic Acid may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisatracuriumTolfenamic Acid may increase the neuromuscular blocking activities of Cisatracurium.Approved
CisplatinThe risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Tolfenamic Acid.Approved
ClarithromycinThe metabolism of Tolfenamic Acid can be decreased when combined with Clarithromycin.Approved
ClobetasolThe risk or severity of gastrointestinal irritation can be increased when Clobetasol is combined with Tolfenamic Acid.Approved, Investigational
Clobetasol propionateThe risk or severity of gastrointestinal irritation can be increased when Clobetasol propionate is combined with Tolfenamic Acid.Approved
ClobetasoneThe risk or severity of gastrointestinal irritation can be increased when Clobetasone is combined with Tolfenamic Acid.Approved
ClocortoloneThe risk or severity of gastrointestinal irritation can be increased when Clocortolone is combined with Tolfenamic Acid.Approved
Clodronic AcidThe risk or severity of gastrointestinal bleeding can be increased when Tolfenamic Acid is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonidineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Tolfenamic Acid.Approved
ClonixinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Clonixin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Tolfenamic Acid.Approved
CloprednolThe risk or severity of gastrointestinal irritation can be increased when Cloprednol is combined with Tolfenamic Acid.Experimental
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Tolfenamic Acid.Vet Approved
CloranololTolfenamic Acid may decrease the antihypertensive activities of Cloranolol.Experimental
ClorindioneThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Clorindione.Experimental
ClotrimazoleThe metabolism of Tolfenamic Acid can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of hypotension can be increased when Clozapine is combined with Tolfenamic Acid.Approved
CobicistatThe metabolism of Tolfenamic Acid can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Tolfenamic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Tolfenamic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColistimethateThe risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Tolfenamic Acid.Approved, Vet Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Tolfenamic Acid.Approved, Investigational
CorticotropinThe risk or severity of gastrointestinal irritation can be increased when Corticotropin is combined with Tolfenamic Acid.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of gastrointestinal irritation can be increased when Cortisone acetate is combined with Tolfenamic Acid.Approved, Investigational
CortivazolThe risk or severity of gastrointestinal irritation can be increased when Cortivazol is combined with Tolfenamic Acid.Investigational
CrizotinibThe metabolism of Tolfenamic Acid can be decreased when combined with Crizotinib.Approved
CryptenamineThe therapeutic efficacy of Cryptenamine can be decreased when used in combination with Tolfenamic Acid.Approved
CurcuminThe metabolism of Tolfenamic Acid can be decreased when combined with Curcumin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Tolfenamic Acid.Experimental
CyclosporineThe risk or severity of renal failure and hypertension can be increased when Tolfenamic Acid is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe therapeutic efficacy of Cyclothiazide can be decreased when used in combination with Tolfenamic Acid.Approved
Dabigatran etexilateThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Tolfenamic Acid can be decreased when it is combined with Dabrafenib.Approved, Investigational
DalteparinThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Dalteparin.Approved
DanaparoidThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Danaparoid.Approved, Withdrawn
DanazolThe metabolism of Tolfenamic Acid can be decreased when combined with Danazol.Approved
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational, Withdrawn
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Tolfenamic Acid.Approved
DarexabanThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Darexaban.Investigational
DarunavirThe metabolism of Tolfenamic Acid can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Tolfenamic Acid can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinThe therapeutic efficacy of Debrisoquin can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
DeferasiroxThe risk or severity of gastrointestinal bleeding and peptic ulcer can be increased when Tolfenamic Acid is combined with Deferasirox.Approved, Investigational
DefibrotideThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Defibrotide.Approved, Investigational
DeflazacortThe risk or severity of gastrointestinal irritation can be increased when Deflazacort is combined with Tolfenamic Acid.Approved, Investigational
DelaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Delapril.Investigational
DelavirdineThe metabolism of Tolfenamic Acid can be decreased when combined with Delavirdine.Approved
DeserpidineThe therapeutic efficacy of Deserpidine can be decreased when used in combination with Tolfenamic Acid.Approved
DesirudinThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Desirudin.Approved
DesmopressinThe risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Tolfenamic Acid is combined with Desmopressin.Approved
DesmoteplaseThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Desmoteplase.Investigational
DesonideThe risk or severity of gastrointestinal irritation can be increased when Desonide is combined with Tolfenamic Acid.Approved, Investigational
DesoximetasoneThe risk or severity of gastrointestinal irritation can be increased when Desoximetasone is combined with Tolfenamic Acid.Approved
DexamethasoneThe serum concentration of Tolfenamic Acid can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone isonicotinate is combined with Tolfenamic Acid.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Dexketoprofen.Approved, Investigational
DexniguldipineThe therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Tolfenamic Acid.Experimental
DextranThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Dextran.Approved, Investigational, Vet Approved
DiazoxideThe therapeutic efficacy of Diazoxide can be decreased when used in combination with Tolfenamic Acid.Approved
DibekacinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Dibekacin.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tolfenamic Acid.Approved, Vet Approved
DicoumarolThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Dicoumarol.Approved
DiethylnorspermineThe therapeutic efficacy of Diethylnorspermine can be decreased when used in combination with Tolfenamic Acid.Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of gastrointestinal irritation can be increased when Diflorasone is combined with Tolfenamic Acid.Approved
DifloxacinTolfenamic Acid may increase the neuroexcitatory activities of Difloxacin.Vet Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tolfenamic Acid.Approved, Investigational
DifluocortoloneThe risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Tolfenamic Acid.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of gastrointestinal irritation can be increased when Difluprednate is combined with Tolfenamic Acid.Approved
DigoxinTolfenamic Acid may decrease the excretion rate of Digoxin which could result in a higher serum level.Approved
DihydralazineThe therapeutic efficacy of Dihydralazine can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
DihydroergotamineThe risk or severity of hypotension can be increased when Dihydroergotamine is combined with Tolfenamic Acid.Approved, Investigational
DihydrostreptomycinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemThe metabolism of Tolfenamic Acid can be decreased when combined with Diltiazem.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Tolfenamic Acid.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Tolfenamic Acid.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Tolfenamic Acid.Approved
DiphenadioneThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Diphenadione.Experimental
DipyridamoleThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Dipyridamole.Approved
DitazoleThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Ditazole.Approved, Withdrawn
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Tolfenamic Acid.Approved
DorzolamideThe therapeutic efficacy of Dorzolamide can be decreased when used in combination with Tolfenamic Acid.Approved
DoxacuriumTolfenamic Acid may increase the neuromuscular blocking activities of Doxacurium.Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Tolfenamic Acid.Approved
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Tolfenamic Acid.Approved, Investigational
DoxycyclineThe metabolism of Tolfenamic Acid can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Tolfenamic Acid.Approved
DroperidolThe risk or severity of hypotension can be increased when Droperidol is combined with Tolfenamic Acid.Approved, Vet Approved
DrospirenoneThe risk or severity of hyperkalemia can be increased when Tolfenamic Acid is combined with Drospirenone.Approved
Drotrecogin alfaThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Tolfenamic Acid.Withdrawn
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Tolfenamic Acid.Approved
Edetic AcidThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Edetic Acid.Approved, Vet Approved
EdoxabanThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Edoxaban.Approved
EfavirenzThe serum concentration of Tolfenamic Acid can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Tolfenamic Acid.Approved
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
EnalaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Enalaprilat.Approved
EndralazineThe therapeutic efficacy of Endralazine can be decreased when used in combination with Tolfenamic Acid.Experimental
EnoxacinTolfenamic Acid may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Tolfenamic Acid.Experimental
EnzalutamideThe serum concentration of Tolfenamic Acid can be decreased when it is combined with Enzalutamide.Approved
EpanololTolfenamic Acid may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Tolfenamic Acid.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Tolfenamic Acid.Experimental
EplerenoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tolfenamic Acid.Approved
EprosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Eprosartan is combined with Tolfenamic Acid.Approved
ErgotamineThe risk or severity of hypotension can be increased when Ergotamine is combined with Tolfenamic Acid.Approved
ErythromycinThe metabolism of Tolfenamic Acid can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololTolfenamic Acid may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololTolfenamic Acid may decrease the antihypertensive activities of Esmolol.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Ethenzamide.Experimental
Ethyl biscoumacetateThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of gastrointestinal bleeding can be increased when Tolfenamic Acid is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Tolfenamic Acid.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Tolfenamic Acid.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Tolfenamic Acid.Approved, Investigational
EtravirineThe serum concentration of Tolfenamic Acid can be decreased when it is combined with Etravirine.Approved
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Tolfenamic Acid.Experimental
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Tolfenamic Acid.Approved
FenoldopamThe therapeutic efficacy of Fenoldopam can be decreased when used in combination with Tolfenamic Acid.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tolfenamic Acid.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Tolfenamic Acid.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fentiazac.Experimental
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Tolfenamic Acid.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Tolfenamic Acid.Experimental
FibrinolysinThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Fibrinolysin.Investigational
FimasartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Tolfenamic Acid.Approved, Investigational
FirocoxibThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Firocoxib.Experimental, Vet Approved
FleroxacinTolfenamic Acid may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Tolfenamic Acid.Approved, Withdrawn
FlomoxefThe risk or severity of nephrotoxicity can be increased when Flomoxef is combined with Tolfenamic Acid.Investigational
FlucloroloneThe risk or severity of gastrointestinal irritation can be increased when Fluclorolone is combined with Tolfenamic Acid.Experimental
FluconazoleThe metabolism of Tolfenamic Acid can be decreased when combined with Fluconazole.Approved, Investigational
FludrocortisoneThe risk or severity of gastrointestinal irritation can be increased when Fludrocortisone is combined with Tolfenamic Acid.Approved, Investigational
FluindioneThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Fluindione.Approved, Investigational
FlumequineTolfenamic Acid may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of gastrointestinal irritation can be increased when Flumethasone is combined with Tolfenamic Acid.Approved, Vet Approved
FlunisolideThe risk or severity of gastrointestinal irritation can be increased when Flunisolide is combined with Tolfenamic Acid.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of gastrointestinal irritation can be increased when Fluocinolone Acetonide is combined with Tolfenamic Acid.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of gastrointestinal irritation can be increased when Fluocinonide is combined with Tolfenamic Acid.Approved, Investigational
FluocortinThe risk or severity of gastrointestinal irritation can be increased when Fluocortin is combined with Tolfenamic Acid.Experimental
FluocortoloneThe risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Tolfenamic Acid.Approved, Withdrawn
FluorometholoneThe risk or severity of gastrointestinal irritation can be increased when Fluorometholone is combined with Tolfenamic Acid.Approved, Investigational
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Tolfenamic Acid.Approved, Investigational, Withdrawn
FluperoloneThe risk or severity of gastrointestinal irritation can be increased when Fluperolone is combined with Tolfenamic Acid.Experimental
FluprednideneThe risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Tolfenamic Acid.Approved, Withdrawn
FluprednisoloneThe risk or severity of gastrointestinal irritation can be increased when Fluprednisolone is combined with Tolfenamic Acid.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Tolfenamic Acid.Vet Approved
FlurandrenolideThe risk or severity of gastrointestinal irritation can be increased when Flurandrenolide is combined with Tolfenamic Acid.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tolfenamic Acid.Approved, Investigational
FluticasoneThe risk or severity of gastrointestinal irritation can be increased when Fluticasone is combined with Tolfenamic Acid.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of gastrointestinal irritation can be increased when Fluticasone furoate is combined with Tolfenamic Acid.Approved
Fluticasone propionateThe risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Tolfenamic Acid.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Tolfenamic Acid.Experimental
FluvoxamineThe metabolism of Tolfenamic Acid can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Fondaparinux.Approved, Investigational
ForasartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Forasartan is combined with Tolfenamic Acid.Experimental
FormocortalThe risk or severity of gastrointestinal irritation can be increased when Formocortal is combined with Tolfenamic Acid.Experimental
FosamprenavirThe metabolism of Tolfenamic Acid can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Tolfenamic Acid can be increased when it is combined with Fosaprepitant.Approved
FoscarnetThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Foscarnet.Approved
FosinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Fosinopril.Approved
FosinoprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Fosinoprilat.Experimental
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Tolfenamic Acid.Approved, Investigational
FramycetinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Framycetin.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Tolfenamic Acid.Approved, Vet Approved
Fusidic AcidThe serum concentration of Tolfenamic Acid can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabexateThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Gabexate.Investigational
GallamineTolfenamic Acid may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideTolfenamic Acid may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GarenoxacinTolfenamic Acid may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinTolfenamic Acid may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Tolfenamic Acid.Approved, Withdrawn
GemifloxacinTolfenamic Acid may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Geneticin.Experimental
GentamicinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with GENTAMICIN C1A.Experimental
GliclazideThe protein binding of Gliclazide can be decreased when combined with Tolfenamic Acid.Approved
GlipizideThe protein binding of Glipizide can be decreased when combined with Tolfenamic Acid.Approved, Investigational
GlyburideThe protein binding of Glyburide can be decreased when combined with Tolfenamic Acid.Approved
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
GrepafloxacinTolfenamic Acid may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Guacetisal.Experimental
GuanabenzThe therapeutic efficacy of Guanabenz can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
GuanadrelThe therapeutic efficacy of Guanadrel can be decreased when used in combination with Tolfenamic Acid.Approved
GuanazodineThe therapeutic efficacy of Guanazodine can be decreased when used in combination with Tolfenamic Acid.Experimental
GuanethidineThe therapeutic efficacy of Guanethidine can be decreased when used in combination with Tolfenamic Acid.Approved
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
GuanoclorThe therapeutic efficacy of Guanoclor can be decreased when used in combination with Tolfenamic Acid.Experimental
GuanoxabenzThe therapeutic efficacy of Guanoxabenz can be decreased when used in combination with Tolfenamic Acid.Experimental
GuanoxanThe therapeutic efficacy of Guanoxan can be decreased when used in combination with Tolfenamic Acid.Experimental
HalcinonideThe risk or severity of gastrointestinal irritation can be increased when Halcinonide is combined with Tolfenamic Acid.Approved, Investigational, Withdrawn
HalometasoneThe risk or severity of gastrointestinal irritation can be increased when Halometasone is combined with Tolfenamic Acid.Experimental
HaloperidolThe therapeutic efficacy of Haloperidol can be increased when used in combination with Tolfenamic Acid.Approved
HeparinThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Heparin.Approved, Investigational
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Tolfenamic Acid.Experimental
HexobarbitalThe metabolism of Tolfenamic Acid can be increased when combined with Hexobarbital.Approved
HydralazineTolfenamic Acid may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tolfenamic Acid.Approved, Vet Approved
HydrocortisoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Tolfenamic Acid.Approved, Vet Approved
Hydrocortisone aceponateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone aceponate is combined with Tolfenamic Acid.Experimental, Vet Approved
Hydrocortisone acetateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Tolfenamic Acid.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Tolfenamic Acid.Approved, Vet Approved
Hydrocortisone probutateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone probutate is combined with Tolfenamic Acid.Approved, Vet Approved
Hydrocortisone succinateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone succinate is combined with Tolfenamic Acid.Approved
Hydrocortisone valerateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone valerate is combined with Tolfenamic Acid.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
Hydrolyzed CephalothinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Hydrolyzed Cephalothin.Experimental
Hygromycin BThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Hygromycin B.Vet Approved
IbandronateThe risk or severity of gastrointestinal bleeding can be increased when Tolfenamic Acid is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tolfenamic Acid.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Tolfenamic Acid.Withdrawn
IcosapentThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Icosapent.Approved, Nutraceutical
IdelalisibThe metabolism of Tolfenamic Acid can be decreased when combined with Idelalisib.Approved
IdraparinuxThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Idraparinux.Investigational
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Tolfenamic Acid.Approved
IloprostThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Iloprost.Approved, Investigational
ImatinibThe metabolism of Tolfenamic Acid can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Imidazole salicylate.Experimental
ImipramineThe risk or severity of hypotension can be increased when Imipramine is combined with Tolfenamic Acid.Approved
Incadronic acidThe risk or severity of gastrointestinal bleeding can be increased when Tolfenamic Acid is combined with Incadronic acid.Approved, Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tolfenamic Acid.Approved
IndenololTolfenamic Acid may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Tolfenamic Acid can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tolfenamic Acid.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Tolfenamic Acid.Withdrawn
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Tolfenamic Acid.Withdrawn
IrbesartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Irbesartan is combined with Tolfenamic Acid.Approved, Investigational
IsavuconazoleThe serum concentration of Tolfenamic Acid can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Tolfenamic Acid can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Isepamicin.Experimental
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Tolfenamic Acid.Approved
IsoniazidThe metabolism of Tolfenamic Acid can be decreased when combined with Isoniazid.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Tolfenamic Acid.Withdrawn
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
ItraconazoleThe metabolism of Tolfenamic Acid can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Tolfenamic Acid can be increased when it is combined with Ivacaftor.Approved
KanamycinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Kanamycin.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Tolfenamic Acid.Experimental
KetanserinThe therapeutic efficacy of Ketanserin can be decreased when used in combination with Tolfenamic Acid.Investigational
KetoconazoleThe metabolism of Tolfenamic Acid can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tolfenamic Acid.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tolfenamic Acid.Approved
LabetalolTolfenamic Acid may decrease the antihypertensive activities of Labetalol.Approved
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Tolfenamic Acid.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Tolfenamic Acid.Approved
LandiololTolfenamic Acid may decrease the antihypertensive activities of Landiolol.Investigational
LatamoxefThe risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Tolfenamic Acid.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
LepirudinThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Lepirudin.Approved
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
LetaxabanThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Letaxaban.Investigational
LevobetaxololTolfenamic Acid may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololTolfenamic Acid may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinTolfenamic Acid may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Tolfenamic Acid.Approved
LinsidomineThe therapeutic efficacy of Linsidomine can be decreased when used in combination with Tolfenamic Acid.Experimental
LisinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Lisinopril.Approved, Investigational
Lithium cationTolfenamic Acid may decrease the excretion rate of Lithium cation which could result in a higher serum level.Experimental
LofexidineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
LomefloxacinTolfenamic Acid may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Lonazolac.Experimental
LopinavirThe metabolism of Tolfenamic Acid can be decreased when combined with Lopinavir.Approved
LoracarbefThe risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Tolfenamic Acid.Investigational, Withdrawn
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Tolfenamic Acid.Approved, Investigational
LorpiprazoleThe serum concentration of Tolfenamic Acid can be increased when it is combined with Lorpiprazole.Approved
LosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Tolfenamic Acid.Approved
LoteprednolThe risk or severity of gastrointestinal irritation can be increased when Loteprednol is combined with Tolfenamic Acid.Approved
LovastatinThe metabolism of Tolfenamic Acid can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Tolfenamic Acid.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
LuliconazoleThe serum concentration of Tolfenamic Acid can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Tolfenamic Acid can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Tolfenamic Acid.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Tolfenamic Acid.Vet Approved
MacitentanThe therapeutic efficacy of Macitentan can be decreased when used in combination with Tolfenamic Acid.Approved
Magnesium carbonateThe therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Tolfenamic Acid.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Tolfenamic Acid is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Tolfenamic Acid is combined with Magnesium oxide.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Tolfenamic Acid.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tolfenamic Acid.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Tolfenamic Acid is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
MannitolThe risk or severity of nephrotoxicity can be increased when Mannitol is combined with Tolfenamic Acid.Approved, Investigational
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tolfenamic Acid.Approved, Vet Approved
MedrysoneThe risk or severity of gastrointestinal irritation can be increased when Medrysone is combined with Tolfenamic Acid.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tolfenamic Acid.Approved
MelagatranThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Melagatran.Experimental
MelengestrolThe risk or severity of gastrointestinal irritation can be increased when Melengestrol is combined with Tolfenamic Acid.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tolfenamic Acid.Approved, Vet Approved
MepindololTolfenamic Acid may decrease the antihypertensive activities of Mepindolol.Experimental
MeprednisoneThe risk or severity of gastrointestinal irritation can be increased when Meprednisone is combined with Tolfenamic Acid.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Tolfenamic Acid.Approved, Investigational, Withdrawn
MethohexitalThe metabolism of Tolfenamic Acid can be increased when combined with Methohexital.Approved
MethoserpidineThe therapeutic efficacy of Methoserpidine can be decreased when used in combination with Tolfenamic Acid.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Tolfenamic Acid.Approved
MethotrimeprazineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Tolfenamic Acid.Approved, Investigational
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tolfenamic Acid.Approved
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Tolfenamic Acid.Approved
MethyldopaThe therapeutic efficacy of Methyldopa can be decreased when used in combination with Tolfenamic Acid.Approved
MethylphenobarbitalThe metabolism of Tolfenamic Acid can be increased when combined with Methylphenobarbital.Approved
MethylprednisoloneThe risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Tolfenamic Acid.Approved, Vet Approved
MetipranololTolfenamic Acid may decrease the antihypertensive activities of Metipranolol.Approved
MetocurineTolfenamic Acid may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideTolfenamic Acid may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tolfenamic Acid.Approved
MetoprololTolfenamic Acid may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetyrosineThe therapeutic efficacy of Metyrosine can be decreased when used in combination with Tolfenamic Acid.Approved
MibefradilThe metabolism of Tolfenamic Acid can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Tolfenamic Acid can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Micronomicin.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Tolfenamic Acid.Approved, Experimental
MifepristoneThe serum concentration of Tolfenamic Acid can be increased when it is combined with Mifepristone.Approved, Investigational
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Tolfenamic Acid.Approved, Vet Approved
MinoxidilThe therapeutic efficacy of Minoxidil can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tolfenamic Acid.Approved
MitotaneThe serum concentration of Tolfenamic Acid can be decreased when it is combined with Mitotane.Approved
MivacuriumTolfenamic Acid may increase the neuromuscular blocking activities of Mivacurium.Approved
ModafinilThe serum concentration of Tolfenamic Acid can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of gastrointestinal irritation can be increased when Mometasone is combined with Tolfenamic Acid.Approved, Vet Approved
Mometasone furoateThe risk or severity of gastrointestinal irritation can be increased when Mometasone furoate is combined with Tolfenamic Acid.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Morniflumate.Approved
MoxifloxacinTolfenamic Acid may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
MuzolimineThe therapeutic efficacy of Muzolimine can be decreased when used in combination with Tolfenamic Acid.Experimental
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Tolfenamic Acid.Approved
NadololTolfenamic Acid may decrease the antihypertensive activities of Nadolol.Approved
NadroparinThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Nadroparin.Approved, Investigational
NafamostatThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Nafamostat.Approved, Investigational
NafcillinThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Tolfenamic Acid.Investigational
Nalidixic AcidTolfenamic Acid may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaloxoneThe metabolism of Tolfenamic Acid can be decreased when combined with Naloxone.Approved, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Tolfenamic Acid.Approved, Vet Approved
NeamineThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Neamine.Experimental
NebivololTolfenamic Acid may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of hypotension can be increased when Nefazodone is combined with Tolfenamic Acid.Approved, Withdrawn
NelfinavirThe metabolism of Tolfenamic Acid can be decreased when combined with Nelfinavir.Approved
NemonoxacinTolfenamic Acid may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Neomycin.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tolfenamic Acid.Approved, Investigational
NetilmicinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Netilmicin.Approved, Investigational
NetupitantThe serum concentration of Tolfenamic Acid can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Tolfenamic Acid can be increased when combined with Nevirapine.Approved
NicardipineThe risk or severity of hypotension can be increased when Nicardipine is combined with Tolfenamic Acid.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Tolfenamic Acid.Approved, Investigational
NicorandilThe therapeutic efficacy of Nicorandil can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tolfenamic Acid.Approved
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Tolfenamic Acid.Experimental
NilotinibThe metabolism of Tolfenamic Acid can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tolfenamic Acid.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Tolfenamic Acid.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Nitroaspirin.Investigational
NitroprussideTolfenamic Acid may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NorfloxacinTolfenamic Acid may increase the neuroexcitatory activities of Norfloxacin.Approved
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Tolfenamic Acid.Approved
NS-398The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with NS-398.Experimental
OfloxacinTolfenamic Acid may increase the neuroexcitatory activities of Ofloxacin.Approved
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Tolfenamic Acid.Approved, Investigational
OlaparibThe metabolism of Tolfenamic Acid can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Tolfenamic Acid.Approved, Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tolfenamic Acid.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Tolfenamic Acid is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Omapatrilat.Investigational
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Tolfenamic Acid.Experimental
OrbifloxacinTolfenamic Acid may increase the neuroexcitatory activities of Orbifloxacin.Vet Approved
OsimertinibThe serum concentration of Tolfenamic Acid can be increased when it is combined with Osimertinib.Approved
OtamixabanThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tolfenamic Acid.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Tolfenamic Acid.Approved
Oxolinic acidTolfenamic Acid may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololTolfenamic Acid may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tolfenamic Acid.Approved, Withdrawn
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Tolfenamic Acid.Investigational, Withdrawn
PalbociclibThe serum concentration of Tolfenamic Acid can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Tolfenamic Acid.Approved
PamidronateThe risk or severity of gastrointestinal bleeding can be increased when Tolfenamic Acid is combined with Pamidronate.Approved
PancuroniumTolfenamic Acid may increase the neuromuscular blocking activities of Pancuronium.Approved
ParamethasoneThe risk or severity of gastrointestinal irritation can be increased when Paramethasone is combined with Tolfenamic Acid.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Tolfenamic Acid.Approved
PargylineThe therapeutic efficacy of Pargyline can be decreased when used in combination with Tolfenamic Acid.Approved
ParnaparinThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Parnaparin.Approved, Investigational
ParomomycinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Paromomycin.Approved, Investigational
PazufloxacinTolfenamic Acid may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinTolfenamic Acid may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololTolfenamic Acid may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Tolfenamic Acid.Experimental
PentamidineThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Pentamidine.Approved, Investigational
PentobarbitalThe metabolism of Tolfenamic Acid can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Tolfenamic Acid.Approved
Pentosan PolysulfateThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Perindopril.Approved
PerindoprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Perindoprilat.Experimental
PhenindioneThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Tolfenamic Acid can be increased when combined with Phenobarbital.Approved, Investigational
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Tolfenamic Acid.Approved, Withdrawn
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Tolfenamic Acid.Approved
PhenprocoumonThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Phenprocoumon.Approved, Investigational
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Tolfenamic Acid.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tolfenamic Acid.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Tolfenamic Acid.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Tolfenamic Acid.Approved
PinacidilThe therapeutic efficacy of Pinacidil can be decreased when used in combination with Tolfenamic Acid.Approved
PindololTolfenamic Acid may decrease the antihypertensive activities of Pindolol.Approved, Investigational
PipecuroniumTolfenamic Acid may increase the neuromuscular blocking activities of Pipecuronium.Approved
Pipemidic acidTolfenamic Acid may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Tolfenamic Acid.Approved
Piromidic acidTolfenamic Acid may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tolfenamic Acid.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Pitolisant.Approved, Investigational
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Tolfenamic Acid.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
PlazomicinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Plazomicin.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Tolfenamic Acid.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Tolfenamic Acid.Approved, Vet Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tolfenamic Acid.Approved
PosaconazoleThe metabolism of Tolfenamic Acid can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
Potassium CitrateThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Potassium Citrate.Approved, Investigational, Vet Approved
PractololTolfenamic Acid may decrease the antihypertensive activities of Practolol.Approved
PralatrexateTolfenamic Acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Pranoprofen.Experimental, Investigational
PrasugrelThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Prasugrel.Approved
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Tolfenamic Acid.Approved
PrednicarbateThe risk or severity of gastrointestinal irritation can be increased when Prednicarbate is combined with Tolfenamic Acid.Approved, Investigational
PrednisoloneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Tolfenamic Acid.Approved, Vet Approved
PrednisoneThe risk or severity of gastrointestinal irritation can be increased when Prednisone is combined with Tolfenamic Acid.Approved, Vet Approved
PrednylideneThe risk or severity of gastrointestinal irritation can be increased when Prednylidene is combined with Tolfenamic Acid.Experimental
PrimidoneThe metabolism of Tolfenamic Acid can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidProbenecid may decrease the excretion rate of Tolfenamic Acid which could result in a higher serum level.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Proglumetacin.Experimental
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Tolfenamic Acid.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Propacetamol.Approved, Investigational
PropafenoneTolfenamic Acid may decrease the antihypertensive activities of Propafenone.Approved
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Tolfenamic Acid.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Tolfenamic Acid.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Tolfenamic Acid.Approved, Investigational
PropranololTolfenamic Acid may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Tolfenamic Acid.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Tolfenamic Acid.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Tolfenamic Acid.Vet Approved
Protein CThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Protein C.Approved
Protein S humanThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Protein S human.Approved
ProtocatechualdehydeThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Protocatechualdehyde.Approved
PrucaloprideThe therapeutic efficacy of Prucalopride can be decreased when used in combination with Tolfenamic Acid.Approved
PrulifloxacinTolfenamic Acid may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PuromycinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Puromycin.Experimental
QuetiapineThe risk or severity of hypotension can be increased when Quetiapine is combined with Tolfenamic Acid.Approved
QuinaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Quinapril.Approved, Investigational
QuinaprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Quinaprilat.Experimental
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tolfenamic Acid.Approved
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Tolfenamic Acid.Approved, Investigational
QuinineThe metabolism of Tolfenamic Acid can be increased when combined with Quinine.Approved
RamiprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Ramipril.Approved
RamiprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Ramiprilat.Experimental
RapacuroniumTolfenamic Acid may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RavuconazoleThe therapeutic efficacy of Ravuconazole can be increased when used in combination with Tolfenamic Acid.Investigational
RemikirenThe therapeutic efficacy of Remikiren can be decreased when used in combination with Tolfenamic Acid.Approved
RescinnamineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Rescinnamine.Approved
ReserpineThe therapeutic efficacy of Reserpine can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
ReteplaseThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Reteplase.Approved, Investigational
ReviparinThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Reviparin.Approved, Investigational
RibostamycinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Ribostamycin.Approved, Investigational
RifampicinThe metabolism of Tolfenamic Acid can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Tolfenamic Acid can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Tolfenamic Acid can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Tolfenamic Acid can be increased when combined with Rifaximin.Approved, Investigational
RilmenidineThe therapeutic efficacy of Rilmenidine can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
RimexoloneThe metabolism of Tolfenamic Acid can be increased when combined with Rimexolone.Approved
RiociguatThe therapeutic efficacy of Riociguat can be decreased when used in combination with Tolfenamic Acid.Approved
RisedronateThe risk or severity of gastrointestinal bleeding can be increased when Tolfenamic Acid is combined with Risedronate.Approved, Investigational
RisperidoneThe risk or severity of hypotension can be increased when Risperidone is combined with Tolfenamic Acid.Approved, Investigational
RitonavirThe metabolism of Tolfenamic Acid can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Rivaroxaban.Approved
RobenacoxibThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Robenacoxib.Experimental, Vet Approved
RocuroniumTolfenamic Acid may increase the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Tolfenamic Acid.Approved, Investigational, Withdrawn
RosoxacinTolfenamic Acid may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinTolfenamic Acid may increase the neuroexcitatory activities of Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Tolfenamic Acid.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tolfenamic Acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Tolfenamic Acid.Approved
SaprisartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saprisartan is combined with Tolfenamic Acid.Experimental
SaquinavirThe metabolism of Tolfenamic Acid can be decreased when combined with Saquinavir.Approved, Investigational
SarafloxacinTolfenamic Acid may increase the neuroexcitatory activities of Sarafloxacin.Vet Approved, Withdrawn
SaralasinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saralasin is combined with Tolfenamic Acid.Investigational
SarilumabThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Sarilumab.Approved, Investigational
SaruplaseThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Saruplase.Experimental
SC-236The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with SC-236.Experimental, Investigational
SecobarbitalThe metabolism of Tolfenamic Acid can be increased when combined with Secobarbital.Approved, Vet Approved
SelexipagThe therapeutic efficacy of Selexipag can be decreased when used in combination with Tolfenamic Acid.Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Tolfenamic Acid.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Tolfenamic Acid.Approved
SiltuximabThe serum concentration of Tolfenamic Acid can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Tolfenamic Acid can be increased when it is combined with Simeprevir.Approved
SisomicinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Sisomicin.Investigational
SitafloxacinTolfenamic Acid may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SitaxentanThe therapeutic efficacy of Sitaxentan can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational, Withdrawn
Sodium CitrateThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicThe risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Tolfenamic Acid.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Tolfenamic Acid.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Tolfenamic Acid.Approved
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Tolfenamic Acid.Approved
SotalolTolfenamic Acid may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinTolfenamic Acid may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Spirapril.Approved
SpironolactoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Tolfenamic Acid can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Tolfenamic Acid can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Streptokinase.Approved, Investigational
StreptomycinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Streptomycin.Approved, Vet Approved
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Tolfenamic Acid.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tolfenamic Acid.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Tolfenamic Acid.Approved, Investigational
SulodexideThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Tolfenamic Acid.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Tolfenamic Acid.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Suxibuzone.Experimental
TacrolimusThe risk or severity of renal failure can be increased when Tolfenamic Acid is combined with Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Tolfenamic Acid.Approved
TalinololTolfenamic Acid may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Talniflumate.Approved
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Tolfenamic Acid.Approved, Investigational
TasosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Tolfenamic Acid.Approved
Technetium Tc-99m ciprofloxacinTolfenamic Acid may increase the neuroexcitatory activities of Technetium Tc-99m ciprofloxacin.Investigational
TegaserodThe therapeutic efficacy of Tegaserod can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Tolfenamic Acid can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Tolfenamic Acid can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Tolfenamic Acid.Approved, Investigational
TemafloxacinTolfenamic Acid may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Temocapril.Experimental, Investigational
TenecteplaseThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Tenecteplase.Approved
TenidapThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Tenidap.Experimental
TenofovirThe serum concentration of Tenofovir can be increased when it is combined with Tolfenamic Acid.Experimental, Investigational
Tenofovir alafenamideThe serum concentration of Tenofovir alafenamide can be increased when it is combined with Tolfenamic Acid.Approved
Tenofovir disoproxilTolfenamic Acid may decrease the excretion rate of Tenofovir disoproxil which could result in a higher serum level.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tolfenamic Acid.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Tolfenamic Acid.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Tolfenamic Acid.Approved
TertatololTolfenamic Acid may decrease the antihypertensive activities of Tertatolol.Experimental
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Tolfenamic Acid.Investigational
ThiamylalThe metabolism of Tolfenamic Acid can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Tolfenamic Acid can be increased when combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Tolfenamic Acid.Approved
ThioridazineThe risk or severity of hypotension can be increased when Thioridazine is combined with Tolfenamic Acid.Approved, Withdrawn
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Tolfenamic Acid.Approved
TicagrelorThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Ticagrelor.Approved
TicrynafenThe therapeutic efficacy of Ticrynafen can be decreased when used in combination with Tolfenamic Acid.Withdrawn
Tiludronic acidThe risk or severity of gastrointestinal bleeding can be increased when Tolfenamic Acid is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololTolfenamic Acid may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Tinoridine.Investigational
TinzaparinThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Tinzaparin.Approved
TioclomarolThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Tioclomarol.Experimental
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Tolfenamic Acid.Approved
TipranavirThe metabolism of Tolfenamic Acid can be decreased when combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of gastrointestinal irritation can be increased when Tixocortol is combined with Tolfenamic Acid.Approved, Withdrawn
TobramycinThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Tobramycin.Approved, Investigational
TocilizumabThe serum concentration of Tolfenamic Acid can be decreased when it is combined with Tocilizumab.Approved
TocopherylquinoneThe therapeutic efficacy of Tocopherylquinone can be decreased when used in combination with Tolfenamic Acid.Experimental, Investigational
TolazamideThe protein binding of Tolazamide can be decreased when combined with Tolfenamic Acid.Approved, Investigational
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Tolfenamic Acid.Approved, Vet Approved
TolbutamideThe protein binding of Tolbutamide can be decreased when combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tolfenamic Acid.Approved
TolonidineThe therapeutic efficacy of Tolonidine can be decreased when used in combination with Tolfenamic Acid.Experimental
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Tolfenamic Acid.Approved
TrandolaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Trandolapril.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tolfenamic Acid.Approved
TrazodoneThe risk or severity of hypotension can be increased when Trazodone is combined with Tolfenamic Acid.Approved, Investigational
TreprostinilThe risk or severity of bleeding can be increased when Treprostinil is combined with Tolfenamic Acid.Approved, Investigational
TriamcinoloneThe risk or severity of gastrointestinal irritation can be increased when Triamcinolone is combined with Tolfenamic Acid.Approved, Vet Approved
TriamtereneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tolfenamic Acid.Approved, Vet Approved
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Tolfenamic Acid.Approved, Investigational
TriflusalThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Triflusal.Approved, Investigational
TrilostaneThe risk or severity of gastrointestinal irritation can be increased when Trilostane is combined with Tolfenamic Acid.Approved, Investigational, Vet Approved, Withdrawn
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Tolfenamic Acid.Experimental
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Tolfenamic Acid.Approved
Trolamine salicylateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Trolamine salicylate.Approved
TroleandomycinThe metabolism of Tolfenamic Acid can be decreased when combined with Troleandomycin.Approved
TrovafloxacinTolfenamic Acid may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Troxerutin.Investigational
TubocurarineTolfenamic Acid may increase the neuromuscular blocking activities of Tubocurarine.Approved
UlobetasolThe risk or severity of gastrointestinal irritation can be increased when Ulobetasol is combined with Tolfenamic Acid.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Tolfenamic Acid.Investigational
UrokinaseThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Tolfenamic Acid.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Valsartan is combined with Tolfenamic Acid.Approved, Investigational
VancomycinTolfenamic Acid may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
VecuroniumTolfenamic Acid may increase the neuromuscular blocking activities of Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Tolfenamic Acid.Approved
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Tolfenamic Acid.Approved
VincamineThe therapeutic efficacy of Vincamine can be decreased when used in combination with Tolfenamic Acid.Experimental
VorapaxarThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Vorapaxar.Approved
VoriconazoleThe metabolism of Tolfenamic Acid can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Warfarin.Approved
XimelagatranThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Ximelagatran.Approved, Investigational, Withdrawn
XipamideThe therapeutic efficacy of Xipamide can be decreased when used in combination with Tolfenamic Acid.Experimental
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tolfenamic Acid.Approved, Investigational
ZiprasidoneThe risk or severity of hypotension can be increased when Ziprasidone is combined with Tolfenamic Acid.Approved
ZofenoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of gastrointestinal bleeding can be increased when Tolfenamic Acid is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tolfenamic Acid.Withdrawn
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Tolfenamic Acid.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Pentikainen PJ, Neuvonen PJ, Backman C: Human pharmacokinetics of tolfenamic acid, a new anti-inflammatory agent. Eur J Clin Pharmacol. 1981;19(5):359-65. [PubMed:7238564]
  2. Tokola RA, Neuvonen PJ: Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol. 1984 Jan;17(1):67-75. [PubMed:6691890]
  3. Lees P, McKellar QA, Foot R, Gettinby G: Pharmacodynamics and pharmacokinetics of tolfenamic acid in ruminating calves: evaluation in models of acute inflammation. Vet J. 1998 May;155(3):275-88. [PubMed:9638074]
  4. McKellar QA, Lees P, Gettinby G: Pharmacodynamics of tolfenamic acid in dogs. Evaluation of dose response relationships. Eur J Pharmacol. 1994 Mar 3;253(3):191-200. [PubMed:8200415]
  5. Kankaanranta H, Moilanen E, Vapaatalo H: Tolfenamic acid inhibits leukotriene B4-induced chemotaxis of polymorphonuclear leukocytes in vitro. Inflammation. 1991 Apr;15(2):137-43. [PubMed:1649132]
  6. Jaussaud P, Guieu D, Bellon C, Barbier B, Lhopital MC, Sechet R, Courtot D, Toutain PL: Pharmacokinetics of tolfenamic acid in the horse. Equine Vet J Suppl. 1992 Feb;(11):69-72. [PubMed:9109966]
  7. Laznicek M, Senius KE: Protein binding of tolfenamic acid in the plasma from patients with renal and hepatic disease. Eur J Clin Pharmacol. 1986;30(5):591-6. [PubMed:3758148]
  8. Pedersen SB: Biopharmaceutical aspects of tolfenamic acid. Pharmacol Toxicol. 1994;75 Suppl 2:22-32. [PubMed:7816776]
  9. EMA [Link]
  10. European Journal of Chemistry [Link]
  11. Clotam leaflet [Link]
  12. EMA [Link]
External Links
Human Metabolome Database
HMDB0042043
KEGG Drug
D01183
PubChem Compound
610479
PubChem Substance
310265123
ChemSpider
530683
BindingDB
35905
ChEBI
32243
ChEMBL
CHEMBL121626
PharmGKB
PA166049189
HET
TLF
Wikipedia
Tolfenamic_acid
ATC Codes
M01AG02 — Tolfenamic acid
PDB Entries
4g77 / 5ikt / 6ap6
MSDS
Download (25.5 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)207ºC Deriv of anthranilic acid, related structurally to mefenamic and flufenamic acids. (1966)
water solubility1 mg/ml'MSDS'
logP5.17US-EPA
pKa5.11Mefenamic acid: analytical profile. (2005)
Predicted Properties
PropertyValueSource
Water Solubility0.0158 mg/mLALOGPS
logP4.64ALOGPS
logP5.49ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)3.88ChemAxon
pKa (Strongest Basic)-2.1ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area49.33 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity71.65 m3·mol-1ChemAxon
Polarizability26.46 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-1290000000-90928e5629bf0b4869e8
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a59-2790000000-175a0f838779d665e3db

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Aminobenzoic acids
Alternative Parents
Benzoic acids / Aminotoluenes / Aniline and substituted anilines / Benzoyl derivatives / Chlorobenzenes / Aryl chlorides / Vinylogous amides / Amino acids / Secondary amines / Monocarboxylic acids and derivatives
show 6 more
Substituents
Aminobenzoic acid / Benzoic acid / Benzoyl / Aniline or substituted anilines / Aminotoluene / Chlorobenzene / Halobenzene / Toluene / Aryl chloride / Aryl halide
show 18 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
organochlorine compound, secondary amino compound, aminobenzoic acid (CHEBI:32243)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Lees P, McKellar QA, Foot R, Gettinby G: Pharmacodynamics and pharmacokinetics of tolfenamic acid in ruminating calves: evaluation in models of acute inflammation. Vet J. 1998 May;155(3):275-88. [PubMed:9638074]
  2. McKellar QA, Lees P, Gettinby G: Pharmacodynamics of tolfenamic acid in dogs. Evaluation of dose response relationships. Eur J Pharmacol. 1994 Mar 3;253(3):191-200. [PubMed:8200415]
  3. Tokola RA, Neuvonen PJ: Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol. 1984 Jan;17(1):67-75. [PubMed:6691890]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Lees P, McKellar QA, Foot R, Gettinby G: Pharmacodynamics and pharmacokinetics of tolfenamic acid in ruminating calves: evaluation in models of acute inflammation. Vet J. 1998 May;155(3):275-88. [PubMed:9638074]
  2. McKellar QA, Lees P, Gettinby G: Pharmacodynamics of tolfenamic acid in dogs. Evaluation of dose response relationships. Eur J Pharmacol. 1994 Mar 3;253(3):191-200. [PubMed:8200415]
  3. Tokola RA, Neuvonen PJ: Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol. 1984 Jan;17(1):67-75. [PubMed:6691890]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Uesawa Y, Takeuchi T, Mohri K: Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17. [PubMed:22039822]

Drug created on October 21, 2015 10:21 / Updated on August 02, 2018 06:15